Rikavarin-S en es it fr

Rikavarin-S Brand names, Rikavarin-S Analogs

Rikavarin-S Brand Names Mixture

  • No information avaliable

Rikavarin-S Chemical_Formula


Rikavarin-S RX_link


Rikavarin-S fda sheet

Rikavarin-S FDA

Rikavarin-S msds (material safety sheet)

Rikavarin-S MSDS

Rikavarin-S Synthesis Reference

No information avaliable

Rikavarin-S Molecular Weight

388.458 g/mol

Rikavarin-S Melting Point

188.7 oC

Rikavarin-S H2O Solubility

40 mg/L

Rikavarin-S State


Rikavarin-S LogP


Rikavarin-S Dosage Forms

Capsules (300 mg) for oral administration; Suppositories (200 mg); Injectable (100 mg, 200 mg)

Rikavarin-S Indication

For the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.

Rikavarin-S Pharmacology

Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate.

Rikavarin-S Absorption

The relative bioavailability of the capsule formulation compared to the solution is 100%.

Rikavarin-S side effects and Toxicity

Oral LD50 in mice is 1600 mg/kg.

Rikavarin-S Patient Information

No information avaliable

Rikavarin-S Organisms Affected

Humans and other mammals